Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?

ConclusionsNAFLD could be dealt with laparoscopic sleeve gastrectomy, preventing its progression into cirrhosis. SG can be performed in patients with obesity and metabolic syndrome, with NAFLD showing satisfactory results 12  months after surgery. NAFLD should be a formal indication for bariatric surgery.
Source: Obesity Surgery - Category: Surgery Source Type: research

Related Links:

AbstractThe growing burden of non-alcoholic fatty liver disease (NAFLD) parallels the increasing prevalence of obesity in Asia. The overall prevalence of NAFLD in Asia is now estimated to be 29.6% and may have surpassed that in Western populations. NAFLD increases with increasing age and is closely associated with metabolic syndrome. Ethnic differences exist in the prevalence of NAFLD, but the underlying factors are unclear. There were initial concerns about lean NAFLD being associated with more severe liver disease and increased mortality, but subsequent studies suggested otherwise. Only some NAFLD patients progress to de...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Fatty liver disease is characterized by a series of pathological conditions ranging from hepatic lipid accumulation (steatosis), to hepatocyte degeneration (ballooning), inflammation (steatohepatitis) and, eventually, cirrhosis and hepatocellular carcinoma [1,2]. Fatty liver disease may be the result of long-term excessive ethanol consumption, (alcoholic liver disease), or of visceral obesity and metabolic syndrome without ethanol consumption, leading to nonalcoholic fatty liver disease (NAFLD) which can evolve to nonalcoholic steatohepatitis (NASH) [3].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
[Microbiome &NASH - partners in crime driving progression of fatty liver disease]. Z Gastroenterol. 2019 Jul;57(7):871-882 Authors: Wree A, Geisler LJ, Tacke F Abstract Along with the increasing prevalence of obesity, metabolic syndrome and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and poses a major challenge for gastroenterologists. Many studies have demonstrated that the microbiome is closely associated with the progression of nutrition-related diseases, especially of fatty liver disease. Changes in the quantity and quality of the intestinal flora, commonly...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
Abstract Non-alcoholic fatty liver disease (NAFLD) is histologically classified as either non-alcoholic fatty liver or non-alcoholic steatohepatitis (NASH). NASH is the progressive subtype of NAFLD. Individuals with NASH are at significant risk of developing hepatic fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related and all-cause mortality. NAFLD is closely associated with obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome, and cardiovascular events. Its prevalence is estimated to be above 30% in Turkey; and recent studies confirm this estimate. According to these studies, the prevalence of...
Source: The Turkish Journal of Gastroenterology - Category: Gastroenterology Authors: Tags: Turk J Gastroenterol Source Type: research
Ali Mahzari1, Songpei Li1, Xiu Zhou1,2, Dongli Li2, Sherouk Fouda1, Majid Alhomrani1, Wala Alzahrani1, Stephen R. Robinson1 and Ji-Ming Ye1,2* 1Lipid Biology and Metabolic Disease Laboratory, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China The present study investigated the effects of matrine on non-alcoholic steatohepatitis (NASH) in mice induced by a methionine choline-deficient (MCD) diet and the mechanism involved. The study was performed in C57B/6J mice fed a MCD diet for 6 weeks to induce NAS...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Martín Mateos R, Allen AM Abstract Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as the most common cause of chronic liver disease worldwide, with a global prevalence of 25.2%. The high burden of NAFLD extends beyond liver diseases, as patients are at risk of developing not only liver related conditions, including cirrhosis and hepatocellular carcinoma, but also cardiovascular complications associated to metabolic syndrome. The present special issue of The Spanish Journal of Gastroenterology (Revista Española de Enfermedades Digestivas) focusses on diverse key aspects o...
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
Abstract Hepatocellular carcinoma (HCC) is the sixth most common cancer in world and third largest cause of cancer-related deaths. The last few decades have witnessed the emergence of non-viral causes of HCC, the most important being non-alcoholic fatty liver disease (NAFLD). NAFLD ranges from simple steatosis in the absence of excessive alcohol intake to non-alcoholic steatohepatitis (NASH) with or without cirrhosis. About 3-15 per cent of the obese patients with NASH progress to cirrhosis and about 4-27 per cent of NASH with cirrhosis patients transform to HCC. It is also known that HCC can develop de novo in pa...
Source: Indian J Med Res - Category: Research Authors: Tags: Indian J Med Res Source Type: research
This study provides evidence that loss of Repin1 in the liver attenuates NAFLD progression, most likely by reducing fat accumulation and alleviating chronic tissue inflammation. Thus, modulating Repin1 expression may become a novel strategy and potential tool to inhibit NAFLD progression.Graphical abstract
Source: Journal of Advanced Research - Category: Research Source Type: research
The burden associated with non-alcoholic fatty liver disease (NAFLD) is becoming a major problem for health systems worldwide.1 As part of the metabolic syndrome, NAFLD prevalence is increasing in parallel with the epidemics of obesity and diabetes;2 although in most cases NAFLD remains a non-progressive disease, in some cases non-alcoholic steatohepatitis (NASH) and progressive fibrosis may occur, finally progressing to cirrhosis and hepatocellular carcinoma.3 Thus, the costs associated with liver disease of metabolic origin and its complications are likely to soon outweigh the costs of liver diseases of viral origin.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Research Article Source Type: research
AbstractPurpose of ReviewIn this review, we examine the interaction between the metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD) and describe the impact of the features of MS on the most worrisome complications of non-alcoholic steatohepatitis (NASH), (cirrhosis, hepatocellular carcinoma) and, ultimately, on liver-related, cardiovascular, and overall mortality.Recent FindingsInsulin resistance, obesity, and dyslipidemia in a pro-inflammatory environment have a causal role in hepatic fibrogenesis and oncogenesis in NAFLD patients. Natural history, longitudinal studies confirm the conditions linked to MS...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
More News: Alcoholism | Bariatric Surgery | Cancer & Oncology | Carcinoma | Cirrhosis | Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Gastrectomy | Gastroenterology | Hepatocellular Carcinoma | Laparoscopy | Liver | Liver Cancer | Liver Disease | Liver Transplant | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Pathology | PET Scan | Statistics | Study | Surgery | Transplant Surgery | Transplants | Urology & Nephrology | Weight Loss